Background Despite evidence that optimal care for diabetes can result in reduced complications and improved economic outcomes, such care is often not achieved. The Vermont Diabetes Information System (VDIS) is a registry-based decision support and reminder system based on the Chronic Care Model and targeted to primary care physicians and their patients with diabetes. PurposeTo develop and evaluate a regional decision support system for patients with diabetes.
. There is increasing evidence that management of associated cardiac risk factors, in particular hypertension and dyslipidemia, results in reduced macrovascular complications [11, 12] . One study, using an approach targeted at treatment of hyperglycemia, hypertension, dyslipidemia, microalbuminuria and cardiac risk reduction with aspirin, achieved a 50% reduction in cardiovascular and microvascular complications [13] .
Despite evidence that optimal care can result in reduced complications and improved economic outcomes, such care is often not achieved [14] [15] [16] [17] . A recent study of outcomes in diabetic patients from the National Health and Nutrition Examination Survey found that 37% had poor glycemic control (A1C > 8%), 40% had blood pressure values > 140/ 90 mm Hg, and over half had cholesterol levels greater than 200 mg/dL. In total, only 7.3% of patients were on target for all three indicators [17] .
Although it is generally accepted that expert, best-practice, clinical guidelines will lead to improvement in clinical care processes and outcomes [18] , these effects may not persist without a comprehensive and ongoing system for quality improvement [19] [20] [21] [22] . Decision support information is a key element in future efforts to improve clinical performance. Decision support is difficult to provide without an information system that can provide reminders, alerts and feedback to the provider (and patient) at the point of care.
Several studies have reported improvement in outcomes for diabetic patients by using populationbased, decision support approaches. These studies have been conducted largely in staff-model managed care organizations with robust information systems [23] [24] [25] . The majority of health care in the US is, however, delivered in settings where a wide variety of insurance plans are accepted and a central information system is not used.
We have developed and implemented a regional evidence-based disease management system for primary care providers and their patients called VDIS (Vennont Diabetes Information System). The system supports primary care providers in meeting treatment targets for management of diabetes and associated vascular risk factors. Our primary goal in this randomized controlled trial is to study the effect of the information system (including patient and physician reminders, feedback and decision support) on disease control as measured by glycosolated hemoglobin AlC (AQC). Secondary questions address the effect of the system on hyperlipidemia, renal monitoring and function, adherence to guideline recommendations, blood pressure, patient satisfaction, medication use, and functional status. We hypothesize that the information system will result in improvements in the process and outcomes of clinical care. In this paper, we describe the design and implementation of the system and the baseline characteristics of the study population.
Methods
VDIS is a decision support and reminder system for primary care practices and their patients with diabetes. It is based on the principles of quality improvement of Donabedian [26] and the Chronic Care Model of illness management [27, 28] . The Chronic Care Model emphasizes the importance of bringing together for an ideal clinical encounter a prepared, proactive health care team and an informed, activated patient. Chronic disease registries are a central aspect of this model. While other implementations of the chronic care model require substantial investment by the practice and major changes in the providers' usual activities, we designed VDIS to require a minimum of effort and no new financial resources on the part of the providers.
VDIS is a joint effort of the study investigators, the Vermont Program for Quality in Health Care (VPQHC) and The North East Community Laboratory Alliance (NECLA). VPQHC is a nonprofit peerreview organization founded in 1988 with a mission to develop and implement a system of quality design and measurement in Vermont. The board of directors includes representatives of consumers, hospitals, insurers, employers, physicians and state government. NECLA is a regional network of community-based clinical laboratories formed in 1996 to provide patients and physicians with coordinated access to high quality, cost-effective laboratory services that improve the health status of local communities [29] . The network currently includes 13 of the 14 acute care hospitals in Vermont. One of the network's missions is to develop and share disease management strategies. The development and evaluation of VDIS is funded by the US National Institute of Diabetes and Digestive and Kidney Diseases (ROl DK61167).
Technical description of VDIS
There are five defining components that characterize VDIS: 1) use of the Chronic Care Model as an organizing framework; 2) daily data feeds from otherwise independent laboratories; 3) automatic test interpretation using algorithms based on consensus guidelines; 4) use of fax and mail to report to providers and patients not easily reached by electronic networks; and 5) report formats that are accessible and useful to patients and providers.
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The primary function of the system is to collect pertinent clinical information and to provide accurate and timely flow sheets, reminders, and alerts to physicians and their patients with diabetes. Secondly, the system generates summary population reports for physicians regarding their roster of diabetic patients. The intended effects of the interventions are outlined in Table 1 .
Data loading
For each participating practice, an initial list of patients is developed by the laboratory, based on all patients who have had an AlC test performed in the previous two years. This list is verified by the primary care provider (PCP) to determine the eligibility of each patient. Once the PCP has verified the list, the patient demographic data are loaded into a custom Oracle data repository.
Subsequently, the laboratory prepares a two-year historical report of laboratory results for those patients and this information is loaded into the database for seeding of flow sheets, reminders and alerts. The laboratory results that are pertinent to management of most patients with diabetes, and that are the subject of guideline recommendations, are the A1C, serum lipid tests, urinary Nightly data collection and processing
The collection of the laboratory data in a timely manner is essential to the creation and distribution of the flow sheets. A nightly program automatically reports that day's A1C, lipid, microalbumin and creatinine results on the population of identified subjects. This file is transferred using file transfer protocol (FTP) and a variety of secure connection methods. Most of the connections are done via branch-to-branch virtual private network (VPN) connections over the Internet or private leased data lines. These daily report files are then processed into the registry database. The system also allows manual data input via a secure Internet forms software function. The software accepts the medical record number and test results and processes them into the registry. This function allows practices performing point of care testing in the office to directly enter test results.
Report triggering
The report generator function runs automatically each night after results are received. Any laboratory result for A1C, LDL, creatinine or MCR triggers the creation and faxing to the PCP of a flow sheet displaying the current results, the previous four results in the database (to display trends), and decision support recommendations based on published guidelines [30, 31] . If a result is above a threshold level, an alert letter is electronically sent to a mail and production service for mailing to the patient. If a patient is overdue for a laboratory test, an alert fax is sent to the' provider, and a letter is mailed to the patient to remind them both of the recommended testing. See the Appendix for examples of these outputs. None of the VDIS output is part of the permanent medical record and does not require filing in the chart. The laboratories continue to send their routine reports to the practices.
The thresholds for designating a result to be high were taken from a Vermont guideline [30] based on the American Diabetes Association Clinical Practice Recommendations [31] for a change in therapy (AlC > 8%; LDL > 130 mg/dL; MCR > 300 pg/Mg).
An AlC is overdue if the previous AlC is more than six months old, or if the previous AlC is 7.0% or greater and more than three months old. A one month grace period is allowed, so a patient reminder letter is not generated until seven or four months have elapsed. A six to 12 month overdue Clinical Trials 2004; 1: 532-544 www.SCTjournal.com period (plus the one month grace period) is applied to LDL and MCR depending on the result range. Since microalbumin testing is often stopped after the development of proteinuria (and appropriate therapy with medications directed at the reninangiotensin system), we suppress MCR reminders once the patient has microalbuminuria.
Quarterly population reports are intended to provide the PCP with a population-based view of his or her roster of diabetic patients. PCPs are encouraged to use the roster for identification of patients who are off guideline or lost to follow-up. The population report also contains comparisons of individual PCP performance with the performance of the entire study population for both on-target and on-time with guideline-based goals. We also include a top 10% performance measure, the achievable benchmark of care [32, 33] .
Practices and study subjects
Laboratories were recruited for VDIS through the Northeast Community Laboratory Alliance and personal communication with laboratory directors and hospital administrators. Eight of the 14 hospital-based laboratories in Vermont as well as four in nearby New York and another in nearby New Hampshire have joined the study. Ten are currently reporting data in the project. Technical personnel from each laboratory work with the investigators to create a secure connection for the daily transmission of laboratory results.
To be eligible, an internal medicine or family medicine practice must: 1) use one of the participating laboratories; 2) care for patients with diabetes;
3) be able to receive faxes; and 4) provide consent.
Practices using point of care testing devices for a small proportion of their testing were invited to participate if we were able to arrange for an efficient method of data acquisition. This was accomplished by daily fax of point of care test results to the VDIS office and web-based data entry into the system by VDIS staff. Some of the largest practices in the state, most notably the faculty practices of the University of Vermont, were not eligible to participate because they were involved in pilot work for this study.
We identified and contacted 141 practices that were potentially eligible for participation in the study from the customer lists of the participating labs and by personal communication with providers around the state. Practices were invited to participate in the project by mail, phone and presentations at grand rounds or medical staff meetings at four of the hospitals. Twenty-two practices were ineligible for the following reasons: practice uses point of care testing device for AlC or lipids making data acquisition impractical (nine); practice participating in a conflicting practice improvement study (six); practice changes such as a new practice, retiring or ill provider (four); scope of practice does not include diabetes care (two); practice uses an EMR that includes reminder and decision support functions (one). Of the 119 eligible practices, 74 (62%) agreed to participate in the study; 45 practices (38%) declined participation or did not respond to multiple attempts at contact. Introductory meetings were held with interested practices to explain the project and solicit participation. If a practice agreed to participate, all PCPs from the practice gave written informed consent. An overview of the principles of the Chronic Care Model and the current Vermont Department of Health diabetes treatment guidelines were provided.
Once a practice was enrolled, a list of all patients with a test for AlC in the previous two years was generated by the laboratory. These lists were reviewed by each PCP to identify those patients who met the following eligibility criteria: 1) diabetes type 1 or type 2; 2) age 18 or older; 3) under the care of that PCP for diabetes; and 4) not suffering from cognitive impairment that would prevent understanding reminders, per the judgment of the PCP. Any conflicts were resolved by discussion with the PCP offices. If a patient was receiving the majority of diabetes care from an endocrinologist or other provider, they were not included on the final PCP roster. We did not distinguish between Type 1 and Type 2 diabetes because the ADA guidelines do not differ substantially regarding testing frequency or therapeutic goals, and because it is often unclear clinically which type of diabetes is present. If a new patient with diabetes is encountered in the course of the study, they may be added to the system for clinical purposes, but are not part of the study population.
A practice is affiliated with one and only one laboratory. We desired to ensure that no laboratory had a gross preponderance of active or control practices. Each laboratory represented a stratum in a stratified and blocked randomization scheme. A series of numbered, sealed, opaque envelopes were created for each stratum (each laboratory). The envelopes contained a card indicating either CONTROL or ACTIVE condition. Blocks of four or six envelopes were filled with balanced numbers of ACTIVE and CONTROL cards, sealed, and shuffled thoroughly within blocks. In that way, each stratum was likely to have an approximately equal number of active and control practices. After each practice was recruited and consented, the next envelope in their laboratory stratum's series was opened to determine the assignment for that practice. The practice was chosen as the unit of randomization because of the sharing of patients and systems of care among PCPs in the same office. Intervention Clinical Trials 2004; 1: 532-544 www.SCTjournal.com practices receive the VDIS intervention while the control practices have patient data collected behind the scenes, and otherwise continue with usual care. The initial practice start date was 5 June 2003 and the most recent practice start date is 18 September 2004. New practices continue to be enrolled and randomized as new labs are brought into the study.
Consent process and privacy issues
Decision support services (such as the information systems, registry functions, reminders, and reports of VDIS) are clinical quality improvement activities that require personal health information as defined and protected under the Health Insurance Portability and Accountability Act (HIPAA). Providers may generally conduct such activities without a specific consent from the patient, although certain restrictions apply such as protection of patient confidentiality. To ensure that the registry data could not be accessed by others, VDIS is structured as a regional quality improvement initiative under the direction and supervision of the Vermont Program for Quality in Health Care (VPQHC), a state chartered peer-review organization. Vermont law protects findings, reports and deliberations of peer review activities from legal discovery, thereby relieving any potential concem on the part of the practices or laboratories that the data could be used to embarrass or legally disadvantage them (Vermont 26 VSA Sec 144, et seq.).
Research activities face stricter regulations under HIPAA and the federal "common rule" governing human investigations and generally require patients to provide informed consent. With identical language, however, both sets of regulations allow an Institutional Review Board (IRB) or Privacy Board to waive active consent if the study meets four criteria set out in Federal guidelines [45CFR46 §46.116(d)]: "An IRB may approve a consent procedure which does not include, or which alters, some or all of the elements of informed consent set forth in this section, or waive the requirements to obtain informed consent provided the IRB finds and documents that: 1) the research involves no more than minimal risk to the subjects; 2) the waiver or alteration will not adversely affect the rights and welfare of the subjects; 3) the research could not practicably be carried out without the waiver or alteration; and 4) whenever appropriate, the subjects will be provided with additional pertinent information after participation".
Because it meets all four criteria, the study protocol was approved by the University's Committee for the Protection of Human Subjects, by legal review at VPQHC, and by further legal and IRB review at the participating hospital labs. An additional special review was held at the National Institutes of Health.
Although not required by law, we employ a passive ("opt-out") consent process for inviting patients into the study. After the patient is identified, but before any services are initiated, we mail a letter to the patient on behalf of the PCP. The letter describes the study and invites the patient to participate. It requests that the patient call the provider or a toll-free number at the University, if they prefer not to participate. All laboratory data for these patients are removed from the database.
We considered using an active ("opt-in") consent process for VDIS that requires each potential subject to sign and return a traditional consent form. We saw this as a potentially fatal flaw in that it would have likely resulted in a greatly reduced sample size and would have introduced a response bias that would limit generalizabilty. In an evaluation of community-based interventions that are designed to be easily reproducible in common clinical settings, it is especially important to have the study population closely resemble the target population.
The PCPs are also considered subjects of this research. Therefore, each participating provider signs an informed consent agreement.
VDIS survey
One advantage of the design of VDIS is that, once the connection to the lab is made, the cost of acquisition of lab data is negligible. One disadvantage is that these data are limited to laboratory results, sex and date of birth. In order to obtain a deeper understanding of the study population and the impact of the intervention, we designed a survey targeted at a randomly selected 10% subsample of patient subjects. Practice rosters are randomly sorted and patients invited by phone to participate in an in-home interview consisting of a questionnaire, measurement of height using a portable stadiometer (SECA, Inc.), weight (LB Dial Scale HAP200KD-41, Healthometer, Inc.), blood pressure (Omron automated sphygmomanometer, Model HEM-71 1) and administration of a test of health literacy. Blood pressure is obtained in the seated position in the left arm (unless contraindicated), using the cuff size recommended by the manufacturer. Three readings are obtained at five-minute intervals and are averaged for the final result. The research assistant reviews questionnaires for completeness at the time of the interview. www.SCTjournal.com enrolled in the substudy provide full written informed consent before they are interviewed. Table 2 lists the variables included in the VDIS study, including those in the survey.
The Medical Outcomes Trust SF-12 is a widely used, validated instrument for assessment of general (rather than disease-specific) functional status [34] . Summary scales covering mental and physical [34] The Audit of Diabetes-Dependant Quality of Life [36] Summary of Diabetes Self Care Activities Measure [61] Self-report of visits to primary care, emergency room, endocrinology, ophthalmology, diabetes educator, dietician Self-report of diabetes complications Self Administered Comorbidity Questionnaire [39] Primary Care Assessment Survey [42] Paper Standard Gamble [37] Patient Health Questionnaire-9 [62] functioning are calculated: the physical component summary and the mental component summary.
The Audit of Diabetes-Dependant Quality of Life is an 18-item questionnaire regarding the impact of diabetes on specific aspects of a person's life with patient weighting of the impact of each domain [35, 36] .
Another approach to health related quality of life is to measure the subject's quantitative preference for their current health. This measure, called "utility", is widely used in cost-effectiveness analyses and other economic studies. The Paper Standard Gamble is a one page assessment of patient utility that has been validated for use in postal surveys [37] .
The Self-Administered Comorbidity Questionnaire is a modification of the widely used Charlson Index. It uses patient interview or questionnaire rather than chart abstraction for assessment of comorbidity and has excellent agreement with the chart-based Charlson Index [38, 39] .
The Short Test of Functional Health Literacy in Adults is a seven-minute timed instrument that measures the ability to read health-related material [40, 41] .
The Primary Care Assessment Survey is a validated, 51-item patient-completed questionnaire designed to measure the essential elements of primary care. It measures seven characteristics of primary care through 11 summary scales: accessibility, continuity, comprehensiveness, integration of care, clinical interaction, interpersonal treatment, and trust [42] .
The Patient Health Questionnaire-9 is a brief selfreport instrument that quantifies the presence and degree of mental depression [43] .
Statistical approach
This is a two-arm randomized trial with clustering by practice. Our primary null hypothesis is that there will be no difference between the intervention and control groups in mean AiC level at study's end. Secondary analyses will focus on group differences in lipids, creatinine, proportion on guideline, and proportion adhering to specific guideline components (overdue for specific tests or out of range for specific tests). We will use a general linear mixed model for outcomes with normally distributed residual errors, or a generalized linear mixed model for outcomes with binomial distribution for residual errors [44] . The primary analysis will include all participants and use final hemoglobin AlC as the dependent variable. Independent variables will be dichotomous variables representing randomization status (1 = active; 0 = control) and patient sex, and continuous variables representing hemoglobin AIC at baseline and patient age. Since the unit of Clinical Trials 2004; 1: 532-544 www.SCTjournal.com randomization is the practice, we will adjust all standard errors for clustering on practice.
Clustering reduces statistical power in proportion to the degree that subjects within each cluster are similar. To account for this, we modeled sample size using the methods of Donner and others [45] [46] [47] , which require an estimate of the intraclass (or within practice) correlation coefficient to use in a variance inflation factor. Initial data from VDIS indicate a standard deviation of AlC of 1.4% and an intra-class correlation of 0.02. There are, on average, 125 eligible subjects per practice. Using alpha = 0.05 and a power of 80%, we require 20 randomized practices (10 per arm) to detect a difference between control and active groups of 0.3%. To detect a difference of only 0.2% requires 44 randomized practices per arm. Currently, 55 practices have been activated and another 17 are in the process of coming into the system.
Results
We report on the 10 hospitals, 55 practices, 121 primary care providers and 7348 patients who are currently active in the VIDS system. The baseline characteristics of the patient population are shown in Table 3 . The demographic characteristics match the population of Vermont [48] .
Two hundred and seven invited patients have declined participation. The refusal rate is 207/7555 or 2.7%. Patients cite a variety of reasons including "feeling too ill", "too old", concerns regarding privacy and sharing of lab data and not identifying oneself as a diabetic.
The number of primary care providers per practice averages 2.1 with a range of 1-6. Of the PCPs, 93 are physicians, 13 are nurse practitioners and 15 are physician assistants. The mean PCP panel size is 59 patients with a range of 1-201. The mean practice panel size is 125 patients with a range of 12-353.
Discussion
Despite evidence that optimal care of diabetes can result in reduced complications and improved economic outcomes, such care is often not achieved [14] [15] [16] [17] . We have developed and are testing a registry-based system that delivers decision support, reminders and population reporting to the primary care provider, and aims to provide patient activation and knowledge through reminders and alerts to patients regarding their own lab results. Our primary analytic goal is to determine the impact of the intervention on glycemic control. Our intervention was designed to incorporate many aspects of the Chronic Care Model. This model has been promoted as a paradigm for overcoming barriers to optimal care of patients with chronic conditions by the Robert Wood Johnson Foundation in their improving chronic illness care program [27, 28, 49] . The Health Disparities Collaborative, supported by the US Health Resources and Services Administration is using the model to support chronic illness care in federally qualified Community Health Centers [50] . The model includes aspects of traditional case management which been found to be effective in improving outcomes in diabetes [51] .
Our design raises important issues regarding the role of patient consent for studies based on disease registries. A recent report on the impracticability of active consent for a Canadian stroke network highlighted the biases introduced by the consent process [52] . Ingelfinger, in an accompanying editorial, highlights several examples of important problems experienced by registries related to privacy and consent issues. We have been successful in recruiting almost 8000 patients into a registry that is overseen by an independent peer review and quality Clinical Trials 2004; 1: 532-544 www.SCTjournal.com improvement organization. Our refusal rate has been very low at 2.7%. HIPAA and IRB regulations have provisions that allow for the use of registries in conducting clinical research which were vital to the implementation of this project. We have learned that the passive consent process is acceptable to patients and providers in this trial. Of the 207 patients who declined to participate in the study, only three raised significant concems about potential violations of privacy. These cases have resulted in interesting discussions with the IRB and the Data Safety Monitoring Board as this type of trial represents new territory for these boards. As an extension of this trial, we are planning further study of the patient and provider experience with the consent process.
Several studies have reported improvement in outcomes for diabetic patients by using populationbased, decision support approaches in staff-model managed care organizations with robust information systems [23] [24] [25] . The majority of health care in the US though, is delivered in settings where a wide variety of insurance plans are accepted and a central information system is not used. There have been reports describing improvements in diabetes clinical process measures in these settings using population-based approaches, but many of these studies suffer from limitations such as a single-institution setting, lack of physiologic outcomes, short duration or observational design [53-581. Like many of these studies, our quarterly population reports provide a current roster of patients for each PCP, sorted by level of control of A1C, lipids and urinary albumin excretion. This allows the provider to identify patients who may benefit from a more intensive intervention. We have deliberately not required a specific case management approach because we are working with a diverse group of practices with widely varying office processes. A mandated case management approach would add significantly to the burden on the practice and on the cost of the intervention itself. Practice participation in VDIS does not require additional personnel, or require a major change in the office processes or referral patterns of the participating practices. In designing the system, we focused on avoiding data entry and minimizing roster maintenance by the primary care practice staff or providers. We feel that this approach would be reproducible in any environment where a single clinical lab provides the bulk of services for each patient. It is potentially adaptable to other clinical conditions where laboratory testing plays a central role in the management of a chronic illness, such as hyperlipidemia and thyroid disorders.
Peer comparison can be a potent stimulus for providers to examine their office processes and may stimulate a practice to implement systematic improvements. For this reason, our quarterly population report provides two benchmarks: 1) the top performing 10% of providers in the VDIS registry, using the achievable benchmark of control approach [32] [33] ; and 2) the American Diabetes Association Provider Recognition Program benchmark. There are significant limitations to the use of physician report cards, particularly in settings where the average patient panel size is small, which we point out to our participating PCPs [59, 60] .
Limitations
One of the limitations of our study design is that if we find improved outcomes in the intervention group, the relative effect of the various components of the intervention will not be known. The effect may, in fact, vary by provider or by patient. Some providers may actively use the population report to track down patients who are lost to follow up, while others may respond to the flow sheets. Likewise, patients are likely to be at varying levels of engagement in the care process and may respond differently to notification about specific results versus overdue reminders. However, given the low marginal cost per patient of providing the entire collection of services, it may not matter exactly which component is most effective.
In some ways, the study population may not generalize to other groups around the country and the world. Our subjects are less racially diverse than the rest of the country, more rural, and less likely to have access to specialty care. However, they are similar to other American diabetes patients in regard to their age, income, sex, comorbid conditions, tobacco use, functional status, and other social and demographic characteristics. Importantly, they get their diabetes care from PCPs without high-tech electronic medical records.
Point-of-care testing devices are becoming more widely used for the office measurement of A1C, MCR and lipids. If data from these devices are not captured in an electronic format, then they are not available for formatting and reporting to the practices or patients by VDIS. We have eliminated some practices that rely heavily on such machines. In several cases, we developed special hand data entry systems for practices with relatively low use of on-site testing. Unfortunately, this is not feasible on a large scale. The importance of developing interfaces between point-of-care testing devices and central laboratory computers or electronic health records has been recognized [61] . 
Conclusions
Our experience to date indicates that a low cost decision support and information system based on the Chronic Care Model is feasible in primary care practices that lack sophisticated electronic information systems. VDIS is well accepted by patients, providers, and laboratory staff. If proven beneficial in a rigorous, randomized, controlled evaluation, the intervention could be widely disseminated to practices across America and the world with a substantial impact on the outcomes and costs of diabetes. It could also be adapted to other chronic conditions. We anticipate the results of the study will be available in 2006. In an effort to improve the quality of health care we provide, our practice is using a new system to help track the care of our patients who have diabetes or who are at high risk of getting diabetes. The Stay on Target -Stay on Time system allows us to identify patents who are not meeting diabetes treatment targets recommended by the American Diabetes Association and the Vermont Department of Health. Now, in addition to the lab sending me a report when you have a diabetes test done, the system will notify you if a result is too high or when you are overdue for a diabetes test. Your LDL (Low Density Lipoprotein) is 158 and is above the target range. Ideal goal for LDL is less than 100, though up to 130 is sometimes acceptable.
If you haven't reviewed these results with someone from our health care team or don't have an appointment scheduled in the near future, please call our office so that we can schedule one for you. In 
